Table 1 Studies characteristics and main antithrombotics for all the studied diseases.
Author, year | Study acronym | Design | Disease | Studied treatment | Comparison(s) | No. of patients |
|---|---|---|---|---|---|---|
Koudstaal, 1993 | EAFT | Open | AF | Warfarin adj stand INR 2.5–4.0, aspirin 300 mg | Placebo | 1007 |
BÜller, 2008 | AMADEUS | PROBE | AF | Idraparinux 2.5 mg od | Warfarin INR 2–3 | 4576 |
Connolly, 2006 | ACTIVE W | Open | AF | Aspirin 75-100 mg + Clopidogrel 75 mg | VKA adj stand INR 2–3 | 6706 |
Connolly, 2011 | AVERROES | DB | AF | Apixaban 5 mg bid | Aspirin 81 to 324 mg | 5599 |
Connolly, 1991 | CAFA | DB | AF | Warfarin adj stand INR 2–3 | Placebo | 378 |
Connolly, 2009 | RE-LY | PROBE | AF | Dabigatran 110/150 mg bid | Warfarin INR 2–3 | 18,113 |
Diener, 1996 | ESPS-2 | DB | AF | Aspirin 25 mg bid, Dipyridamole 200 mg + Aspirin 25 mg bid, Dipyridamole 200 mg bid | Placebo | 6602 |
Ezekowitz, 1992 | SPINAF | DB | AF | Warfarin adj stand INR 1.4–2.8 | Placebo | 525 |
Giugliano, 2013 | ENGAGE AF-TIMI | DB | AF | Edoxaban 30/60 mg od | Warfarin INR 2–3 | 21,105 |
Granger, 2011 | ARISTOTLE | DB | AF | Apixaban 5 mg bid | Warfarin INR 2–3 | 18,201 |
Gullov, 1998 | AFASAK II | Open | AF | Aspirin 300 mg od, Warfarin 1.25 mg + Asprin 300 mg od, warfarin | Warfarin adj stand INR 2–3 | 677 |
Halperin, 2005 | SPORTIF V | DB | AF | Ximelagatran 36 mg bid | Warfarin INR 2–3 | 3922 |
Hellemons, 1999 | PATAF | Open | AF | Aspirin 150 mg od | Acenocoumarol | 729 |
Hori, 2012 | J-ROCKET AF | DB | AF | Rivaroxaban 15 mg od | Warfarin INR 2–3 | 1280 |
Kistler, 1990 | BAATAF | PROBE | AF | Warfarin adj stand INR 1.5–2.7 | No treatment | 420 |
Lip, 2009 | NCT00684307 | PROBE | AF | AZD0837 300 mg od | Warfarin INR 2–3 | 471 |
Mant, 2007 | BAFTA | PROBE | AF | Warfarin adj stand INR 2–3 | Aspirin 75 mg od | 973 |
McBride, 1991 | SPAF I | Open | AF | Aspirin 325 mg od, Warfarin adj stand INR 2–4.5 | Placebo | 1330 |
McBride, 1996 | SPAF III | PROBE | AF | Warfarin adj low INR 1.2–1.5 + Aspirin 325 mg od | Warfarin adj stand INR 2–3 | 1044 |
Morocutti, 1997 | SIFA | Open | AF | Indobufen 200 mg bid or 100 mg bid | Warfarin adj stand INR 2–3.5 | 916 |
Olsson, 2003 | SPORTIF III | PROBE | AF | Ximelagatran 36 mg bid | Warfarin INR 2–3 | 3407 |
Pérez-Gomez, 2004 | NASPEAFa | PROBE | AF | Triflusal 600 mg od + coumadin medium dose INR 1.25–2, Triflusal 600 mg od | Coumadin standard dose INR 2–3 | 714 |
Pérez-Gomez, 2004 | NASPEAFb | PROBE | AF | Triflusal 600 mg od + coumadin medium dose INR 1.25–2 | Triflusal 600 mg od | 495 |
Patel, 2011 | ROCKET AF | DB | AF | Rivaroxaban 20 mg od | Warfarin INR 2–3 | 14,264 |
Pengo, 2010 | / | Open | AF | Warfarin adj low INR 1.5–2 | Warfarin adj stand INR 2–3 | 267 |
Sato, 2006 | JAST | Open | AF | Aspirin 150-200 mg od | No treatment | 871 |
Connolly, 2013 | EXPLORE-Xa | DB | AF | Betrixaban 40, 60, 80 mg od | Warfarin INR 2–3 | 254 |
Büller, 2012 | CASSIOPEA | DB | PE | Idrabiotaparinux 3 mg ow | Warfarin INR 2–3 | 3202 |
Büller, 1997 | COLOMBUS | Open | DVt, PE | Reviparin 6300 anti-Xa bid | UFH Bolus 5000 IU then 1250 IU/h | 1012 |
Büller, 2010 | EINSTEIN DVT | PROBE | DVT | Rivaroxaban 15 mg bid then 20 mg od | Enoxaparin 1 mg/kg bid + Warfarin INR 2–3 | 3449 |
Büller, 2008 | EINSTEIN DVT | PROBE | DVT | Rivaroxaban 20 mg od | fraxiparin + VKA INR 2–3 | 273 |
Büller, 2012 | EINSTEIN PE | PROBE | PE + / − DVT | Rivaroxaban 15 mg bid then 20 mg od | Enoxaparin 1 mg/kg bid + Warfarin or acenocoumarol INR 2–3 | 4833 |
Büller, 2011 | EQUINOX | DB | DVT | Idrabiotaparinux 3 mg ow | Idrparinux 2.5 mg ow | 757 |
Büller, 2013 | HOKUSAI VTE | DB | DVt, PE | Edoxaban 60 mg od | Warfarin INR 2–3 | 8292 |
Büller, 2004 | MATISSE DVT | DB | DVT | Fondaparinux 5 mg od | Enoxaparin 1 mg/kg bid | 2205 |
Büller, 2003 | MATISSE PE | PROBE | PE | Fondaparinux 5 mg od | UFH Bolus 5000 IU + 1250 IU/h aPTT | 2213 |
Büller, 2007 | VAN GOGH DVT | PROBE | DVT | Idraparinux 2.5 mg ow | Warfarin INR 2–3 | 2904 |
Büller, 2007 | VAN GOGH PE | PROBE | PE | Idraparinux 2.5 mg ow | Warfarin INR 2–3 | 2215 |
Agnelli, 2013 | AMPLIFY | DB | DVT, PE | Apixaban 10 mg, 5 mg bid | Enoxaparin 1 mg/kg then Warfarin INR 2–3 | 5395 |
Agnelli, 2013 | AMPLIFY EXT | DB | DVT, PE | Apixaban 2.5 mg or 5 mg bid | Placebo | 2486 |
Brandjes, 1992 | / | DB | DVT | UFH Bolus 5000 IU then 1250 IU/h | Placebo | 120 |
Hull, 1992 | / | DB | DVT | LMWH 175 UI/kg od | UFH Bolus 5000 IU | 432 |
Kearon, 2006 | FIDO | PROBE | DVT, PE | LMWH 100 IU/kg | UFH 333 U/kg then 250 U/kg bid | 708 |
Levine, 1996 | / | PROBE | DVT | Enoxaparin 1 mg/kg bid | UFH Bolus 5000 IU then 20000 IU | 500 |
Merli, 2001 | / | PROBE | DVT, PE | Enoxaparin 1 mg/kg bid or 1.5 mg/kg od | UFH | 900 |
Prandoni, 2004 | GALILEI | PROBE | DVT, PE | Nadroparin 80 U/kg bid | UFH 4000 U + 12,500 U | 720 |
Prandoni et al., 1992 | / | Open | DVT | Nadroparin 0.5 ml bid | UFH Bolus 100 IU/kg then 35000 IU od | 170 |
Schulman, 2009 | RE-COVER | DB | DVT, PE | Dabigatran 150 mg bid | Warfarin INR 2–3 | 2539 |
Schulman, 2013 | RE-COVER II | DB | DVT, PE | Dabigatran 150 mg bid | Warfarin INR 2–3 | 2568 |
Schulman, 2013 | RE-MEDY | DB | DVT, PE | Dabigatran 150 mg bid | Warfarin INR 2–3 | 2866 |
Simonneau, 1997 | THÉSÉE | PROBE | PE | Tinzaparin IU/kg od | UFH Bolus 50 IU/kg then 500 IU/kg od | 612 |
Büller, 2007 | VAN GOGH EXT | PROBE | DVT, PE | Idraparinux 2.5 mg ow | Placebo | 1215 |
Eriksson, 2003 | THRIVE I | PROBE | DVT | Enoxaparin 24 mg bid | Dalteparin 200U/kg + Warfarin INR 2–3 | 141 |
Fiessinger, 2005 | THRIVE | DB | DVT + / − PE | Ximelagatran 36 mg bid | Warfarin INR 2–3 | 2528 |
Leizorovicz, 2004 | PREVENT | DB | CHF | Dalteparin 5000 IU od | Placebo | 3706 |
Lederle, 2006 | / | DB | MP | Enoxaparin 4000 IU od | Placebo | 280 |
Samama, 1999 | MEDENOX | DB | CHF | Enoxaparin 4000 IU od | Placebo | 738 |
Fraisse, 2000 | / | DB | PD | Nadroparin 3800–5700 IU | Placebo | 223 |
Mahe, 2005 | DB | AMI | Nadroparin 2850 IU | Placebo | 2474 | |
Diener, 2006 | PROTECT | DB | AIS | Certoparin 3000 IU od | UFH 5000 IU × 3 | 545 |
Riess, 2010 | CERTIFY | DB | MP | Certoparin 3000 IU od | UFH 5000 IU × 3 | 3244 |
Schellong, 2010 | CERTAIN | PROBE | MP | Certoparin 3000 IU od | UFH 7500 IU bid | 337 |
Harenberg, 1990 | / | DB | MP | Dalteparin 2500 IU | UFH 5000 IU × 3 | 166 |
Hillbom, 2002 | / | DB | AIS | Enoxaparin 4000 IU od | UFH 5000 IU × 3 | 212 |
Sherman, 2007 | PREVAIL | PROBE | AIS | Enoxaparin 4000 IU od | UFH 5000 IU bid | 1762 |
Bergmann, 1996 | EMSG | DB | AMI | Enoxaparin 2000 IU | UFH 5000 IU bid | 442 |
Lechler, 1996 | PRIME | DB | MP | Enoxaparin 4000 IU od | UFH 5000 IU × 3 | 959 |
Kleber, 2003 | PRINCE | PROBE | SRD | Enoxaparin 4000 IU od | UFH 5000 IU × 3 | 665 |
Aquino, 1990 | / | Open | MP | Nadroparin 2850 IU | UFH 10,000 or 15,000 IU | 99 |
Manciet, 1990 | APTE | DB | Elderly population | Nadroparin 2850 IU | UFH 5000 IU bid | 256 |
Forette, 1995 | / | Open | Elderly population | Nadroparin 2850 IU | UFH 5000 IU bid | 295 |
Harenberg, 1996 | HESIM | DB | MP | Nadroparin 2850 IU | UFH 5000 IU × 3 | 1590 |
Gardlund, 1996 | / | Open | Infectious disease | UFH 5000 IU bid | No treatment | 11,693 |
Cohen, 2006 | ARTEMIS | DB | AMI | Fondaparinux 2.5 mg od | Placebo | 849 |
Goldhaber, 2011 | ADOPT | DB | AMI | Apixaban 2.5 mg bid | Enoxaparin 4000 IU od | 4972 |
Cohen, 2013 | MAGELLAN | DB | AMI | Rivaroxaban 10 mg od 10/35 days | Enoxaparin 4000 IU od | 8101 |
Cohen, 2016 | APEX | DB | AMI | Betrixaban 160 mg then 80 mg od | Placebo | 7513 |
Hull, 2010 | EXCLAIM | DB | MP | Enoxaparin 4000 IU od | Placebo | 6085 |
Spyropoulos, 2018 | MARINER | DB | MP | Rivaroxaban 10 mg or 7.5 mg od | Placebo | 12,019 |
Levine, 1996 | / | DB | TKR | Ardeparin 50 IU/kg bid | Placebo | 246 |
Leclerc, 1992 | / | DB | TKR | Enoxaparin 3000 IU bid | Placebo | 131 |
Colwell, 1994 | / | Open | HR | Enoxaparin 3000 IU bid or 4000 IU od | UFH 5000 IU × 3 | 610 |
Leyvraz A VALIDER, 1991 | / | Open | TKR | Fraxiparin 41 IU/kg od then 62 IU/kg od | UFH × 3 | 409 |
Haas, 2006 | / | DB | TKR + THR | Reviparin 4200 IU od | UFH 7500 IU bid | 2018 |
Colwell, 1999 | / | Open | Primary hip arthroplasty | Enoxaparin 3000 IU bid | Warfarin 7.5 mg INR 2–3 | 3011 |
Fitzgerald, 2001 | / | PROBE | TKR | Enoxaparin 3000 IU bid | VKA INR 2–3 | 349 |
Leclerc, 1996 | / | DB | TKR | Enoxaparin 3000 IU bid | VKA INR 2–3 | 670 |
Lassen, 2009 | ADVANCE-1 | DB | TKR | Apixaban 2.5 mg bid | Enoxaparin 3000 IU bid | 3195 |
Lassen, 2010 | ADVANCE-2 | DB | TKR | Apixaban 2.5 mg bid | Enoxaparin 4000 IU od | 3057 |
Lassen, 2010 | ADVANCE-3 | DB | THR | Apixaban 2.5 mg bid | Enoxaparin 4000 IU od | 5407 |
Eriksson, 2007 | RE-MODEL | DB | TKR | Dabigatran 150/220 mg | Enoxaparin 4000 IU od | 2101 |
Eriksson, 2007 | RE-NOVATE | DB | THR | Dabigatran 150/ 220 mg od | Enoxaparin 4000 IU od | 3494 |
Eriksson, 2010 | RE-NOVATE-2 | DB | THR | Dabigatran 220 mg od | Enoxaparin 4000 IU od | 2055 |
Ginsberg, 2008 | RE-MOBILIZE | DB | TKR | Dabigatran 150/220 mg od | Enoxaparin 3000 IU bid | 2615 |
Eriksson, 2008 | RECORD 1 | DB | THR | Rivaroxaban 10 mg od | Enoxaparin 4000 IU od | 4541 |
Lassen, 2008 | RECORD 3 | DB | TKR | Rivaroxaban 10 mg od | Enoxaparin 4000 IU od | 2531 |
Turpie, 2009 | RECORD 4 | DB | TKR | Rivaroxaban 10 mg od | Enoxaparin 3000 IU bid | 3148 |
Bauer, 2001 | PENTAMAKS | DB | MKS | Fondaparinux 2.5 mg od | Enoxaparin 3000 IU bid | 1049 |
Eriksson, 2001 | PENTHIFRA | DB | HFS | Fondaparinux 2.5-mg od | Enoxaparin 4000 IU od | 1711 |
Lassen, 2002 | EPHESUS | DB | HFS | Fondaparinux 2.5-mg od | Enoxaparin 4000 IU od | 2309 |
Turpie, 2002 | PENTATHLON | DB | HFS | Fondaparinux 2.5-mg od | Enoxaparin 3000 IU bid | 2275 |
Heit, 2000 | / | DB | THR | Ardeparin 100 IU/kg od | Placebo | 1195 |
Comp, 2001 | / | DB | TKR, THR | Enoxaparin 4000 IU od | Placebo | 873 |
Eriksson, 2003 | PENTHIFRA-Plus | DB | HFS | Fondaparinux 2.5 mg od | Placebo | 656 |
Kakkar, 2008 | RECORD2 | DB | THR | Rivaroxaban 10 mg od | Enoxaparin 40 mg od | 2509 |
Anderson, 2018 | / | DB | THR, TKR | Rivaroxaban 10 mg od | Aspirin 81 mg od | 3424 |
Lassen, 2012 | SAVE-HIP1 | DB | THR | Semuloparin 20 mg od | Enoxaparin 40 mg od | 2326 |
Lassen, 2012 | SAVE-HIP2 | DB | HF | Semuloparin 20 mg od | Enoxaparin 40 mg od | 1003 |
Lassen, 2012 | SAVE-KNEE | DB | TKR | Semuloparin 20 mg od | Enoxaparin 30 mg bid | 1150 |
Fisher, 2013 | SAVE-HIP3 | DB | Upper third of the femur | Semuloparin 20 mg od | Placebo | 469 |
Ho, 1999 | / | PROBE | MCS | Enoxaparin 4000 IU od | No treatment | 303 |
Rasmussen, 2006 | FAME | Open | MAS | Dalteparin 5000 IU od | No treatment | 427 |
Bergqvist, 2002 | ENOXACAN II | DB | MAS | Enoxaparin 4000 IU od | Placebo | 501 |
Kakkar, 2010 | CANBESURE | DB | MAS | Bemiparin 3500 IU od | Placebo | 626 |
Turpie, 2007 | APOLLO | DB | MAS | Fondaparinux 2.5 mg od | Placebo | 1309 |
Agnelli, 2005 | PEGASUS | DB | MAS | Fondaparinux 2.5 mg od | Dalteparin 5000 IU od | 2927 |
Kakkar, 2013 | SAVE-ABDO | DB | ML | Semuloparin 20 mg od | Enoxaparin 40 mg od | 4352 |
Haas, 2012 | TOPIC-1 | DB | CP | Certoparin 3000 IU od | Placebo | 353 |
Haas, 2012 | TOPIC-2 | DB | CP | Certoparin 3000 IU od | Placebo | 547 |
Perry, 2010 | PRODIGE | DB | CP | Dalteparin 5000 U od | Placebo | 186 |
Maraveyas, 2012 | FRAGEM | Open | CP | Gemcitabine | Dalteparin + Gemcitabine 200 IU/kg od then 150 IU/kg | 123 |
Klerk, 2005 | MALT | DB | CP | Nadroparin 9500 U/ml | Placebo | 302 |
Agnelli, 2009 | PROTECHT | DB | CP | Nadroparin 3800 IU od | Placebo | 1150 |
van Doormaal, 2011 | INPACT | PROBE | CP | Nadroparin | Placebo | 503 |
Agnelli, 2012 | SAVE-ONCO | DB | CP | Semuloparin 20 mg od | Placebo | 3212 |
